Deep Pipeline – Large Markets, High Unmet Need
Our lead program is Non-Alcoholic Steatohepatitis (NASH), impacting 16 million people in the U.S. and 100 million worldwide. We are developing predictive biomarkers that allow us to noninvasively and accurately stage NASH with a liquid biopsy better than the current standard of invasive needle liver biopsy. The same liquid biopsy reliably measures response to therapy long before histopathology changes become visible.
Our next program is Oncology, impacting 14 million patients in the U.S. and 50 million worldwide. We are developing a synthetic biomarker-based liquid biopsy to directly track progression of specific cancers and response to treatment longitudinally, across a broad range of immunotherapies, targeted therapies, and other standards-of-care.
Our development pipeline features programs in Oncology and Infections with preclinical validation in 10+ additional diseases.